Anavex Life Sciences (NASDAQ:AVXL – Get Free Report)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report released on Monday,Benzinga reports. They currently have a $46.00 price target on the biotechnology company’s stock. D. Boral Capital’s price target suggests a potential upside of 379.17% from the company’s previous close.
Separately, HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Anavex Life Sciences in a report on Monday, November 4th.
Read Our Latest Research Report on AVXL
Anavex Life Sciences Trading Up 5.4 %
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of AVXL. Renaissance Technologies LLC lifted its stake in Anavex Life Sciences by 483.8% in the 2nd quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after acquiring an additional 386,537 shares in the last quarter. Virtu Financial LLC grew its position in Anavex Life Sciences by 87.5% in the first quarter. Virtu Financial LLC now owns 40,612 shares of the biotechnology company’s stock valued at $207,000 after purchasing an additional 18,954 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in Anavex Life Sciences in the 2nd quarter valued at $346,000. Vanguard Group Inc. lifted its position in Anavex Life Sciences by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 4,414,682 shares of the biotechnology company’s stock worth $22,471,000 after buying an additional 54,034 shares in the last quarter. Finally, Nwam LLC bought a new position in shares of Anavex Life Sciences in the 3rd quarter valued at about $5,172,000. 31.55% of the stock is owned by institutional investors and hedge funds.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Featured Stories
- Five stocks we like better than Anavex Life Sciences
- Best Aerospace Stocks Investing
- 3 Strategic ETFs for Bearish Investors Post-Election
- Investing In Preferred Stock vs. Common Stock
- Super Micro’s Stock Price Is Ready to Rebound After Market Reset
- Roth IRA Calculator: Calculate Your Potential Returns
- 3 Forces Shaping a Bullish 2025 Outlook
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.